Nexalis Therapeutics completes Phase 1 Inhaled CBD trial
Nexalis Therapeutics (ASX:NX1) announced a clinical milestone following the final dosing of its Phase 1 study for IRX-616a.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Nexalis Therapeutics (ASX:NX1) announced a clinical milestone following the final dosing of its Phase 1 study for IRX-616a.
Ausgold (ASX:AUC) has strengthened its executive ranks as it nears a final investment decision for its flagship Katanning Gold Project.
Metaplanet reported first-quarter operating income of 2.27 billion yen ($14.38 million) as revenue from Bitcoin options and derivatives more than tripled from a year earlier.
The Federal Court found that Coles (ASX:COL) misled consumers through its pervasive "Down Down" promotional campaign.
Polymarket recorded its first monthly decline in trading activity since August after trading volume fell about 8.9% in April amid growing competition from rival prediction market operators.
Ampol (ASX:ALD) shares surged as Middle East conflict drives Q1 refinery margins to US$25.45/bbl,
oOh!media (ASX:OML) reported a 7% lift in Australian Q1 revenue, slightly outperforming earlier projections.
Arkham published what it described as a public onchain map linking two OFAC-sanctioned Tron wallets to Iran’s central bank following a $344 million USDT freeze tied to US sanctions enforcement.
Cisco (NASDAQ:CSCO) reported third-quarter fiscal 2026 revenue of $15.8 billion, a 12% increase from the prior-year period.
Michael Saylor’s Strategy has reportedly added an estimated 2,110 Bitcoin after raising fresh capital through its STRC perpetual preferred stock programme.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy